Provided by Tiger Trade Technology Pte. Ltd.

Tenaya Therapeutics Inc

0.6973
+0.00680.98%
Post-market: 0.71000.0127+1.82%19:54 EDT
Volume:1.15M
Turnover:814.54K
Market Cap:156.20M
PE:-1.31
High:0.7200
Open:0.6929
Low:0.6926
Close:0.6905
52wk High:2.35
52wk Low:0.5316
Shares:224.00M
Float Shares:223.00M
Volume Ratio:0.50
T/O Rate:0.52%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.5333
EPS(LYR):-0.5922
ROE:-121.86%
ROA:-47.91%
PB:2.25
PE(LYR):-1.18

Loading ...

Tenaya Therapeutics appoints Eric Hyllengren as CFO

TIPRANKS
·
Jun 29

Press Release: Tenaya Therapeutics Appoints Eric Hyllengren as Chief Financial Officer

Dow Jones
·
Jun 29

Tenaya Therapeutics posts Jefferies healthcare conference deck on heart disease gene therapy pipeline

Reuters
·
Jun 05

Tenaya Therapeutics management to meet with Piper Sandler

TIPRANKS
·
Jun 04

Analysts Offer Insights on Healthcare Companies: Cabaletta Bio (CABA) and Tenaya Therapeutics (TNYA)

TIPRANKS
·
Jun 04

Analysts Are Bullish on Top Healthcare Stocks: Ligand Pharma (LGND), Tenaya Therapeutics (TNYA)

TIPRANKS
·
Jun 04

Tenaya Therapeutics - Cohort 1 Benefits Sustained up to Two Years; Cohort 2 Shows Earlier Improvement

THOMSON REUTERS
·
Jun 03

Tenaya Therapeutics - All Evaluable Patients Show Improvements in Mybpc3-Associated HCM After Tn-201 Treatment

THOMSON REUTERS
·
Jun 03

Tenaya Therapeutics Announces Interim Data From Mypeak™-1 Showing Treatment of Mybpc3-Associated HCM With Tn-201 Gene Therapy Resulted in Consistent Signs of Cardiac Remodeling and Reductions in Symptoms

THOMSON REUTERS
·
Jun 03

Tenaya Therapeutics - Tn-201 Well Tolerated With No New Safety Events Reported

THOMSON REUTERS
·
Jun 03

Tenaya Therapeutics to release new interim MyPEAK-1 trial data for TN-201 gene therapy in MYBPC3-associated HCM on June 3

Reuters
·
Jun 03

Tenaya Therapeutics to Announce New Interim Data From Mypeak™-1 Phase 1B/2 Trial of Tn-201 for Adults With Mybpc3-Associated HCM on Wednesday, June 3, 2026

THOMSON REUTERS
·
Jun 03

Tenaya Therapeutics Shareholders Approve Expanded Equity Incentive Plan

TIPRANKS
·
May 30

Tenaya Therapeutics shareholders approve amended 2021 equity incentive plan at annual meeting

Reuters
·
May 30

Tenaya Therapeutics to Present at Jefferies Global Healthcare Conference

Reuters
·
May 29

Buy Rating Reiterated on Tenaya: Promising TN-401 RIDGE-1 Data, Strong Transgene Expression, and Upcoming Catalysts Support Attractive Risk/Reward

TIPRANKS
·
May 18

Analysts Offer Insights on Healthcare Companies: Tenaya Therapeutics (TNYA), Lineage Therap (LCTX) and RenovoRx (RNXT)

TIPRANKS
·
May 16

Wall Street Analysts Are Bullish on Top Healthcare Picks

TIPRANKS
·
May 16

Analyst Reiterates Buy on Positive TN-401 RIDGE-1 Data Despite Cutting Price Target from $19 to $3

TIPRANKS
·
May 15

Tenaya Shares Rise on Positive Data From ARVC Study

Dow Jones
·
May 15